Herpes Zoster (Shingles): Molecular Pathogenesis, Immune Mechanisms, Clinical Manifestations, Therapeutic Advances, and Prevention Strategies – A Comprehensive Review

Herpes Zoster Varicella-Zoster Virus VZV Reactivation Postherpetic Neuralgia Oxidative Stress

Authors

October 30, 2026

Downloads

The latent varicella-zoster virus (VZV), a member of the Herpesviridae family, reactivates to cause herpes zoster (HZ), sometimes referred to as shingles, a neurocutaneous illness. VZV creates a lifetime delay inside sensory ganglia after primary infection, which typically presents as varicella (chickenpox). When VZV-specific cellular immunity decreases, especially with aging, immunosuppression, or long-term medical problems, the virus reactivates. The clinical presentation of herpes zoster is characterised by unilateral dermatomal pain followed by a vesicular skin eruption; however, severe complications such as postherpetic neuralgia (PHN), ophthalmic involvement, neurological disorders, and disseminated infection may occur.Recent advances have improved understanding of the molecular mechanisms involved in VZV latency, immune regulation, neuroinflammation, and chronic pain development. Antiviral therapies, including acyclovir, valacyclovir, and famciclovir, remain the mainstay of treatment, particularly when initiated early. In addition, recombinant zoster vaccines have significantly improved prevention strategies, especially among older adults and immunocompromised individuals. This review summarizes current knowledge regarding VZV biology, epidemiology, pathogenesis, immune responses, clinical manifestations, diagnosis, treatment approaches, and recent preventive strategies. Understanding the complex interaction between viral persistence and host immunity is essential for improving disease management and reducing herpes zoster-associated morbidity.